Latest News About Vigil

I can’t access live news directly right now, but I can summarize the most recent publicly reported developments about Vigil Neuroscience (VIGL) up to my last update and suggest where to check for the latest.

Direct answer

• Vigil Neuroscience has been involved in its TREM2 agonist programs, with attention to VG-3927 and the Iluzanebart program. Recent reporting around mid-2025 highlighted a potential sale to Sanofi and ongoing clinical updates; however, for the very latest events (dates, approvals, trial results, or mergers), you should consult current financial news sources.

What to look for in the latest coverage

• Mergers and acquisitions: announcements, regulatory approvals, and closing timelines related to any Sanofi deal or other strategic moves.
• Clinical trial updates: Phase 1/2 results for VG-3927, progress in IGNITE and ILLUMINATE studies, and any FDA interactions or accelerated-approval discussions.
• Financial results and guidance: quarterly/annual results, strategic investments, debt/equity financings, and pipeline milestones.
• Litigation and governance: shareholder actions, class actions or investigations tied to the merger or stock activity.

Where to find up-to-date information

• Company press releases on Vigil Neuroscience’s investor relations page.
• Major financial news outlets (Reuters, Bloomberg, CNBC) for merger/earnings coverage.
• Stock/market news aggregators (Yahoo Finance, Bloomberg Markets) and specialized biotech outlets (BioCentury, Endpoints News).
• Regulatory databases (SEC filings) for formal merger documents and financial disclosures.

If you’d like, I can monitor or assemble a brief, up-to-date snapshot if you provide permission to pull current sources, or I can guide you to specific pages to check. Also, tell me if you want a quick comparison table of VG-3927 vs Iluzanebart programs or a chart of Vigil’s stock activity around mid-2025.

Citations

• For any specific claim about Vigil’s strategic moves or trial data, I’ll cite the exact source after delivering the fact.